 -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 GLOBE NEWSWIRE -- La Jolla Pharmaceutical Company Nasdaq: LJPC, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, and Tetraphase Pharmaceuticals, Inc. Nasdaq: TTPH, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM eravacycline to treat serious and life-threatening infections, today announced the closing of La Jollas acquisition of Tetraphase. La Jolla acquired Tetraphase for 43.0 million in upfront cash plus potential future cash payments of up to 16.0 million pursuant to contingent value rights CVRs. The holders of the CVRs are entitled to receive payments of up to an additional 16.0 million in the aggregate upon the achievement of certain net sales of XERAVA in the United States. With two, FDA-approved, innovative therapies for life-threatening diseases, La Jolla is well-positioned to help patients in need, said Larry Edwards, President and Chief Executive Officer of La Jolla. By leveraging the stronger platform that the combined company will provide, we look forward to increasing patient access to these important medicines.About GIAPREZAGIAPREZATM angiotensin II for injection was approved by the U.S. Food and Drug Administration FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA was approved by the European Commission EC for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the bodys endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at The European Summary of Product Characteristics is available on the EMA website: GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.GIAPREZA Important Safety InformationContraindicationsNone.Warnings and PrecautionsThere is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism VTE prophylaxis.Adverse ReactionsThe most common adverse reactions that were reported in greater than 10 of GIAPREZA-treated patients were thromboembolic events.Drug InteractionsAngiotensin converting enzyme ACE inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers ARBs may reduce response to GIAPREZA.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union.About XERAVAXERAVATM eravacycline for injection was approved by the U.S. Food and Drug Administration FDA as a novel fluorocycline of the tetracycline class antibacterials indicated for the treatment of complicated intra-abdominal infections cIAI in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of Tetraphases IGNITE Investigating Gram-Negative Infections Treated with Eravacycline Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. Prescribing information for XERAVA is available at XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla.XERAVA Important Safety InformationXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.XERAVA is not indicated for the treatment of complicated urinary tract infections.To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity anaphylactic reactions have been reported with XERAVA.The use of XERAVA during tooth development last half of pregnancy, infancy and childhood to the age of eight years may cause permanent discoloration of the teeth yellow-gray-brown and enamel hypoplasia.The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.Clostridium difficile associated diarrhea CDAD has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.The most common adverse reactions observed in clinical trials incidence 3 were infusion site reactions, nausea and vomiting.XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.For additional information, please see Full Prescribing Information for the United States.About La Jolla Pharmaceutical CompanyLa Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZATM angiotensin II is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVATM eravacycline is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit StatementsThis press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on managements expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZATM angiotensin II and XERAVATM eravacycline sales; whether La Jolla will realize the benefits from the acquisition of Tetraphase Pharmaceuticals, Inc.; regulatory actions relating to La Jollas products by the U.S. FDA, European Commission andor other regulatory authorities; cash used in operating activities and our capital requirements; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.La Jolla Pharmaceutical Company Contact: Michael Hearne Chief Financial Officer La Jolla Pharmaceutical Company 858 333-5769 